Femasys Inc. is a biomedical company. The Company is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)